Safety of chronic transdermal fentanyl use in patients receiving hemodialysis.
Department of Pharmacy PracticeCollege of PharmacyComprehensive Sickle Cell CenterSection of Hematology/OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, ILjhan35@uic.edu.
Jin
J
Han
Comprehensive Sickle Cell CenterSection of Hematology/OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, IL.
Santosh L
SL
Saraf
Comprehensive Sickle Cell CenterSection of Hematology/OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, IL.
Victor R
VR
Gordeuk
Comprehensive Sickle Cell CenterSection of Hematology/OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, ILmgowha1@uic.edu.
Michel
M
Gowhari
D000279:Administration, Cutaneous; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects
D000701:Analgesics, Opioid; D005283:Fentanyl